|Wednesday, 13 September 2017, 13:25 HKT/SGT|
|The Answer to Viruses and Bacteria in the Home! Eliminates Viruses & Bacteria, Antimicrobial Action that Lasts for 1 Week |
TOKYO, Sept 13, 2017 - (JCN Newswire) - Eisai Co., Ltd. will launch Etak Antimicrobial Spray Alpha (classified as miscellaneous goods), which contains long-acting antimicrobial agent Etak, on September 19 (Tuesday). This product eliminates viruses and bacteria with an antimicrobial action that lasts for one week.
Etak, the main ingredient used in the product, is a long-acting antimicrobial agent developed by Professor Hiroki Nikawa of the Department of Oral Health Engineering at Hiroshima University's Graduate School of Biomedical and Health Sciences. An adhesive component in Etak chemically binds the antimicrobial component to the spray area, providing an antimicrobial effect that lasts for one week.
In the home, there are many surfaces and items, such as doorknobs, bannisters, tables, flooring, and toys, to which viruses and bacteria can spread easily when touched. This product is an answer to the needs of consumers who wish to keep those viruses and bacteria at bay. We suggest habitually using Etak Antimicrobial Spray Alpha to eliminate viruses and bacteria in the home. Additionally, this product contains no alcohol and is both scentless and colorless, making it ideal for use on a wide variety of surfaces and items in the home.
Eisai is also marketing Etak Antimicrobial Spray, an alcohol type spray for mouth masks which uses the same long-acting antimicrobial agent Etak. By spraying it on a mouth mask prior to use, you can prevent viruses and bacteria from collecting on the mask for 24 hours.
Eisai remains committed to ensuring the delivery of products that satisfy the diversified needs of consumers and to making further contributions to increase the benefits provided to them.
1. Product Name: Etak Antimicrobial Spray Alpha (Miscellaneous Goods)
2. Ingredients: Water, long-acting antimicrobial agent (compound containing ethoxysilane), solubilizing agent, stabilizing agent
3. Directions for use:
- Please remove stopper when using. Returning the stopper locks the product.
- Please keep the nozzle 20-30cm away from the target and spray an appropriate amount.
- When using for the first time, please press the spray button a few times to activate the spray mechanism.
- In order to achieve a uniform spread, please wipe the surface with a cloth or other item after spraying.
- Please do not use this product upside down.
4. Volume / Suggested retail price (excluding tax): 250ml / 1,280 yen
5. Manufacturer: Jex Co., Ltd.
6. Supplier: Eisai Co., Ltd.
About long-acting antimicrobial agent Etak
Etak was developed by Professor Hiroki Nikawa of the Department of Oral Health Engineering at Hiroshima University's Graduate School of Biomedical and Health Sciences. It is a patented longacting antimicrobial agent (patent number: 4830075) that combines quaternary ammonium salts, which are also included in hand sanitizers and oral cleansing agents used by dentists, with a silane analogue, an immobilizing agent that functions as adhesive. When a quaternary ammonium salt is sprayed onto an object, it would normally lose its antimicrobial properties upon drying. However, with Etak, the adhesive component chemically binds the antimicrobial component to the spray area, thereby preserving the antimicrobial effect.
Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.
Public Relations Department,
Eisai Co., Ltd.
Sept 13, 2017 13:25 HKT/SGT
Eisai (TSE: 4523)
Topic: Press release summary
From the Asia Corporate News Network
Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|July 19, 2018 09:38 HKT/SGT|
Latest Data on Eisai's Alzheimer's Disease / Dementia Pipeline to be Presented at Alzheimer's Association International Conference (AAIC) 2018|
|July 18, 2018 11:04 HKT/SGT|
Eisai: Positive Topline Results Obtained from Large-Scale Cardiovascular Outcomes Trial of Anti-Obesity Agent BELVIQ|
|July 11, 2018 15:32 HKT/SGT|
Eisai: Oral Antifungal Agent Nailin Capsules 100mg to be Launched in Japan|
|July 10, 2018 10:14 HKT/SGT|
Eisai: Oral Presentation on Phase II Clinical Study Results of BAN2401 to be Presented at Alzheimer's Association International Conference (AAIC) 2018|
|July 9, 2018 14:07 HKT/SGT|
Eisai: Results from Two Phase 3 Clinical Trials of Chronic Constipation Treatment "GOOFICE 5mg Tablet" Published in The Lancet Gastroenterology & Hepatology|
|July 6, 2018 09:31 HKT/SGT|
Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 At 18 Months|
|July 4, 2018 17:18 HKT/SGT|
Eisai Listed for 17th Consecutive Year in FTSE4GOOD Index Series|
|July 2, 2018 15:36 HKT/SGT|
Eisai to Give Oral Presentation on Results of Phase III Head-to-Head Clinical Study of Lemborexant in Insomnia Disorder |
|June 22, 2018 10:58 HKT/SGT|
Eisai Selected for Membership in MSCI Japan Empowering Women Index (WIN)|
|June 21, 2018 09:51 HKT/SGT|
AbbVie and Eisai Announce the Launch of HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL|
|More news >>|